Myrna Hurtado,Umesh T Sankpal,Jaya Chhabra et al.
Myrna Hurtado et al.
The non-steroidal anti-inflammatory drug, Tolfenamic acid (TA) acts as an anti-cancer agent in several adult and pediatric cancer models. Copper (Cu) is an important element with multiple biological functions and has gained interest in medi...
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose [0.03%]
一种针对HER2/HER3双特异性单克隆抗体MCLA-128的转化PK-PD模型分析，预测有效药物浓度和剂量临床试验中的有效性
Aurelia H M de Vries Schultink,Robert P Doornbos,Alexander B H Bakker et al.
Aurelia H M de Vries Schultink et al.
Introduction MCLA-128 is a bispecific monoclonal antibody targeting the HER2 and HER3 receptors. Pharmacokinetics (PK) and pharmacodynamics (PD) of MCLA-128 have been evaluated in preclinical studies in cynomolgus monkeys and mice. The aim ...
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma [0.03%]
伊立替康，卡培他滨和奥沙利铂（IXO）一线治疗转移性胃或胃食管交界处腺癌的多中心开放标签II期临床研究
Arthur Lui,Karen Mulder,Christine Brezden-Masley et al.
Arthur Lui et al.
Purpose Chemotherapy remains the primary treatment for metastatic gastric/GEJ cancer but optimal agents and schedule remain controversial. This study examined the safety and efficacy of first-line Irinotecan, capecitabine (Xeloda®), and Ox...
Clinical Trial
Investigational new drugs. 2018 Aug;36(4):674-682. DOI:10.1007/s10637-018-0599-4 2018
Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report [0.03%]
奥希替尼诱导的发热和肝毒副作用后的口服脱敏治疗案例报告：奥希替尼脱敏治疗成功案例报告
Ryosuke Hirabayashi,Daichi Fujimoto,Yukari Satsuma et al.
Ryosuke Hirabayashi et al.
Osimertinib is a standard second-line therapy for patients who develop EGFR Thr790Met resistance mutation after treatment with first-line epidermal growth factor receptor tyrosine kinase inhibitors. Although no other effective targeted trea...
Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists [0.03%]
人急性髓系白血病细胞表达神经激肽-1受体并参与其受体拮抗剂的抗白血病效应
A Molinos-Quintana,P Trujillo-Hacha,J I Piruat et al.
A Molinos-Quintana et al.
The substance P/neurokinin-1 receptor system has been implicated in tumor cell proliferation. Neurokinin-1 receptor has been identified in different solid tumors but not frequently in hematopoietic malignant cells. We investigated the prese...
Takuya Oyakawa,Nao Muraoka,Kei Iida et al.
Takuya Oyakawa et al.
Crizotinib is a receptor tyrosine kinase inhibitor that has several targets, including c-ros oncogene 1 and the MET proto-oncogene. Considering its known cardiac toxicity, bradycardia is often investigated following treatment with crizotini...
Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides [0.03%]
利用计算设计的肽抑制IL-2信号传导和调节性T细胞途径
Tammy Price-Troska,Zhi-Zhang Yang,David Diller et al.
Tammy Price-Troska et al.
Background Increased serum levels of soluble interleukin-2 (IL-2) receptor alpha (sIL-2Rα) are an indicator of poor prognosis in patients with B-cell non-Hodgkin lymphoma (NHL). By binding to IL-2, sIL-2Rα upregulates Foxp3 expression and...
Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate [0.03%]
用卫菲宁治疗头颈部鳞状细胞癌的瘤内优化疗法
Catherine M E Barnett,Natasa Broit,Pei-Yi Yap et al.
Catherine M E Barnett et al.
The five-year survival rate for patients with head and neck squamous cell carcinoma (HNSCC) has remained at ~50% for the past 30 years despite advances in treatment. Tigilanol tiglate (TT, also known as EBC-46) is a novel diterpene ester th...
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules [0.03%]
DPF-10917两种新的核苷类似物的I期、药代动力学和药效学研究，含14天和7天连续输注方案
Kamalesh Sankhala,Chris H Takimoto,Alain C Mita et al.
Kamalesh Sankhala et al.
Purpose DFP-10917 is a novel deoxycytidine analog with a unique mechanism of action. Brief exposure to high concentrations of DFP-10917 inhibits DNA polymerase resulting in S-phase arrest, while prolonged exposure to DFP-10917 at low concen...
Clinical Trial
Investigational new drugs. 2019 Feb;37(1):76-86. DOI:10.1007/s10637-018-0602-0 2019
Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan [0.03%]
日本罕见抗肿瘤药物监管审批及关键临床研究的特殊性分析
Hiroki Nakayama,Katsura Tsukamoto
Hiroki Nakayama
The approval of orphan anticancer drugs has increased, with the number exceeding that of non-orphan drugs in Japan in recent years. Although orphan anticancer drugs may have unique characteristics due to their rarity, these have not been fu...